ASH Clinical News | Page 35

CLINICAL NEWS LBA-5 Azacitidine Combination Regimens Fail to Improve Overall Response Rate in Higher-Risk MDS The addition of lenalidomide or vorinostat to azacitidine did not improve overall response rates in patients with chronic myelomonocytic leukemia or higher-risk myelodysplastic syndromes, according to an analysis of 276 patients in the phase 2 North American Intergroup (SWOG S1117) study. Overall response rates were similar across all treatment arms: 36 percent in the monotherapy arm, 37 percent for azacitidine + lenalidomide (p=1.0 vs. monotherapy), and 22 percent for azacitidine + vorinostat (p=.07 vs. monotherapy). However, when patients remained on treatment for six months or longer, there was a trend toward greater relapse-free survival in the combination arms – raising questions about whether patients in these arms are remaining on treatment long enough to benefit from the additional therapy. More patients in the combination arms discontinued treatment due to toxicities, side effects, or complications, and had non-protocol defined dose reductions, though, Mikkael Sekeres, MD, MS, first author, noted during his presentation of the data. “We have to wonder if combination regimens in MDS are too toxic, and if we need to manage toxicities better,” Dr. Sekeres said. LBA-6 Mixed Picture for Vosaroxin in Improving Overall Survival in Difficult-to-Treat AML A combination of cytabarine and vosaroxin failed to improve survival for patients with relapsed or refractory acute myeloid leukemia (AML) – a setting in which viable treatment options are sorely lacking. In the phase 3 randomized VALOR trial, 711 adult AML patients with relapsed or refractory disease were randomized to receive cytarabine with either vosaroxin or placebo. Overall survival was similar in patients receiving the vosaroxin/cytabarine combination arm compared to those receiving cytarabine/placebo (7.5 months vs. 6.1 months with placebo; p=0.06). This was despite patients receiving vosaroxin being more likely to achieve complete response (30.1% vs. 16.3% with placebo). Survival was marginally improved in patients receiving vosaroxin when those undergoing bone marrow transplantation were censored from analyses (6.7 vs. 5.3 months, p=0.02). “The benefit was particularly visible in older patients, who experienced manageable added toxicity,” said lead study author Farhad Ravandi, MD. ● ASHClinicalNews.org Rising Cost of Cancer Drugs: Is There an End in Sight? In 2013, U.S. health-care spending continued its relentless climb, reaching $2.9 trillion, far outspending any other developed nation.1 About $271.1 billion of that – or almost one out of every 10 dollars spent on healthcare – was spent on prescription drugs. A recent example of the skyrocketing prices of treating hematologic malignancies: In 2012, three new drugs were approved by the FDA to treat chronic myeloid leukemia (CML), each with an annual price tag of more than $100,000.2 Special Symposium on Quality panelists At the 2014 ASH Annual Meeting, experts tackled the rising cost of cancer drugs and their associated “financial toxicity” in the Special Symposium on Quality with a passionate, and often heated, discussion. As the cost of health care is a difficult subject that requires the attention of the entire medical community, a diverse panel was invited to discuss these challenges. Reducing Burden Without Compromising Outcomes The rising cost of cancer drugs is a relatively new phenomenon, Hagop Kantarjian, MD, of MD Anderson Cancer Center, asserted in his presentation – and one that poses direct harm to patients. “My first awareness of the high cost of cancer drugs was in 2012, and this was 30 years into my career,” he said. Spending on cancer drugs can lead to personal bankruptcy, emotional distress and, potentially, lack of compliance. “I believe that as physicians, we have to protect our patients at the individual and society level,” Dr. Kantarjian said. “When drugs are not affordable, then they are harming the patient.” So, who are the high prices helping? According to Dr. Kantarjian, big pharma is benefitting from unsustainable pricing, and many of the justifications for the rising costs of cancer drugs are unfounded. “You have heard that it costs $1 billion to develop a drug for the market - I think that statement is a myth propagated by the pharmaceutical companies,” he said. Price shouldn’t stifle innovation, he said, “when 85 percent of basic research is funded by taxpayers and 20 percent of earned revenue goes to advertisements.” There are a number of solutions to the problem, Dr. Kantarjian explained, including establishing mechanisms for ensuring fair prices, allowing Medicare to negotiate drug prices, and eliminating the practice of “pay for delay” (in which pharmaceutical companies pay to prevent generic competitors from becoming available). A Natural Market Response? Playing devil’s advocate, Alex W. Bastian, MBA, of GfK Market Access (a health-care consulting firm), argued that current drug prices actually do reflect value and are the result of practical market forces. He also maintained that the cost for cancer care has remain